- Home
- ONMD vs MURA Comparison
ONMD vs MURA Comparison
Compare ONMD & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONMD
- MURA
- Stock Information
- Founded
- ONMD 2006
- MURA 2013
- Country
- ONMD United States
- MURA Ireland
- Employees
- ONMD N/A
- MURA N/A
- Industry
- ONMD
- MURA
- Sector
- ONMD
- MURA
- Exchange
- ONMD Nasdaq
- MURA Nasdaq
- Market Cap
- ONMD 16.5M
- MURA 17.7M
- IPO Year
- ONMD N/A
- MURA N/A
- Fundamental
- Price
- ONMD $0.39
- MURA $2.77
- Analyst Decision
- ONMD
- MURA Strong Buy
- Analyst Count
- ONMD 0
- MURA 4
- Target Price
- ONMD N/A
- MURA $13.00
- AVG Volume (30 Days)
- ONMD 54.3K
- MURA 14.1M
- Earning Date
- ONMD 04-15-2025
- MURA 05-13-2025
- Dividend Yield
- ONMD N/A
- MURA N/A
- EPS Growth
- ONMD N/A
- MURA N/A
- EPS
- ONMD N/A
- MURA N/A
- Revenue
- ONMD $643,000.00
- MURA N/A
- Revenue This Year
- ONMD N/A
- MURA $34.35
- Revenue Next Year
- ONMD N/A
- MURA N/A
- P/E Ratio
- ONMD N/A
- MURA N/A
- Revenue Growth
- ONMD N/A
- MURA N/A
- 52 Week Low
- ONMD $0.30
- MURA $0.95
- 52 Week High
- ONMD $3.37
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- ONMD 30.42
- MURA 61.06
- Support Level
- ONMD $0.45
- MURA $0.98
- Resistance Level
- ONMD $0.55
- MURA $2.79
- Average True Range (ATR)
- ONMD 0.09
- MURA 0.23
- MACD
- ONMD 0.00
- MURA 0.27
- Stochastic Oscillator
- ONMD 34.29
- MURA 80.53
About ONMD OneMedNet Corp
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a global provider of clinical imaging innovation and curator of regulatory-grade Imaging Real-World Data or iRWDTM. OneMedNet's innovative solutions connect healthcare providers and patients satisfying a crucial need within the Life Sciences field offering direct access to clinical images and the associated contextual patient record.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.